SLS 26RS-248 ORIGINALENGROSSED Regular Session SENATE BILL NO.
B.An insurer,pharmacybenefitmanager,orpersonactingonbehalf of a pharmacy benefit manager shall not provide reimbursement on behalf of an OfficeofGroupBenefitsinsuranceplanoranyotherstatesponsoredinsurance plan for any name branddrug,biosimilar,orgenericdrugthatislessthanthepriceMedicarepaysbrand drug, biosimilar, or generic drug that is less than the price Medicare pays for the same drug.
Section 2.
This Act shall become effective on January 1, 2027.
SLS 26RS-248 ORIGINALENGROSSED SB NO.
369 TheSection original2. instrument and the following digest, which constitutes no part of the legislative instrument, were prepared bySenate Legislative Services.
This Act shall become effective on January 1, 2027.
The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared bySenate Legislative Services.
1:13(B) and 24:177(E)] DIGEST SB 369 OriginalEngrossed 2026 Regular Session Bass ProposedlawprohibitsadrugmanufacturerfromsellingadruginthisstateatahigherpriceProposedlawprohibits adrugmanufacturerfromsellingadruginthisstateatahigherprice than the price Medicare pays for the same drug.drug of an Office of Group Benefits (OGB) or other state sponsored insurance plan.
Proposed law prohibits an insurer or pharmacy benefit manager from providing reimbursement for anyanydrug drug less than the price Medicare pays for the same drug.drug of an OGB or other state sponsored insurance plan.
22:1867.1) PageSummary 2 of 2Amendments Coding:Adopted by Senate CommitteeAmendmentsProposedbySenateCommitteeonInsurancetotheoriginal bill 1.
Limit applicability of proposed law relative to health insurance reimbursements to OGB or state sponsored plans.
Page 2 of 2 Coding: